#USA #New Delhi #AI Technology #Datar Cancer Genetics #Chemotherapy Testing

Datar Cancer Genetics Revolutionizes Chemotherapy Effectiveness Testing

In a groundbreaking move, Datar Cancer Genetics (DCG) has launched a novel video-reporting service that significantly enhances in-vitro chemosensitivity testing for cancer patients. This innovative service, which utilizes advanced AI technology, provides oncologists with real-time visual evidence on how chemotherapy drugs act on tumor cells derived from tissue biopsies or blood samples. This crucial advancement meets an urgent need in the realm of precision oncology, enabling doctors to make informed decisions regarding drug selection for their patients.

By allowing oncologists to observe the effects of chemotherapy drugs directly on tumor cells, this service personalizes treatment approaches, reduces the reliance on trial-and-error methods, and minimizes the risks associated with toxicities from ineffective drugs. As of now, the service is available for patients with solid organ tumors, and it comes equipped with comprehensive reporting on both standard-of-care and off-label medications, particularly beneficial for those battling drug-resistant cancers.

The DCG platform employs human-supervised AI technology to meticulously analyze high-resolution, real-time videos of tumor cells responding to various chemotherapy treatments. These time-lapse videos provide clear, verifiable evidence supporting treatment decisions, allowing clinicians to visualize how a patient's cancer might react to multiple therapies before any medication is administered. Dr. Darshana Patil, Senior Director of Global Strategy and Medical Affairs at DCG, highlights the significance of this technology: "For the first time, we can see how a patient's cancer cells respond to various chemotherapy treatments before administration."

Chemotherapy has long been a fundamental aspect of cancer treatment; however, its efficacy can be hampered by empirical drug selection. The absence of molecular biomarkers for many available therapies typically increases the risk of both ineffective outcomes and adverse side effects. DCG's groundbreaking platform addresses this challenge head-on, thereby improving decision-making processes and patient outcomes while reducing the risks commonly associated with ineffective therapies.

Key Features of the New Video-Reporting Service

1. Real-time Visualization: Patients and their healthcare teams can see the immediate effects of chemotherapy on tumor cells, providing tangible evidence to guide treatment decisions.
2. Comprehensive Drug Analysis: The platform analyzes various treatment options, including standard-of-care and off-label drugs, streamlining the selection process for oncologists.
3. Automated AI-Driven Quantification: The service offers precise metrics regarding tumor cell elimination rates, making treatment selection quicker and more efficient.
4. Transparency in Treatment Choices: The video format ensures a patient-friendly experience, fostering open communication regarding treatment plans and expectations.
5. Demonstrated Success: The technology has been validated through rigorous clinical trials and is already in use at major oncology centers, marking improved treatment success rates and increased patient contentment.

Dr. Vineet Datta, Senior Director of Global Strategy and Business Development at DCG, expressed his enthusiasm about the potential for this service to transform cancer care: "This evidence-based approach revolutionizes cancer care by enhancing transparency and optimizing treatment selection."

For a demonstration of how the platform operates, interested parties can view a video at this link.

About Datar Cancer Genetics

Datar Cancer Genetics is a leading player in the global oncology field, dedicated to creating non-invasive solutions for cancer detection and treatment. With accredited facilities located in both the UK and India, DCG provides its innovative services to cancer patients worldwide, continuously pushing the boundaries of precision cancer care.